Cambridge Healthtech Institute’s Inaugural

Cancer Immunotherapy

Emerging Biology, Targets and Strategies

March 7 – 9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

 

Cancer immunotherapy, hailed as the biggest breakthrough in modern cancer treatment, has quickly permeated mainstream basic and clinical research. With vast excitement seen over the past few years stirred by remarkable clinical efficacy of immunotherapy agents, the emergence and rapid growth of biotechs and pharmaceutical partnering, and recent regulatory approvals of checkpoint inhibitors and T-cell engagers, it has become clear that immuno-oncology research and the development of immunotherapies and their combinations will continue to revolutionize cancer treatment. 

Cambridge Healthtech Institute’s inaugural Cancer Immunotherapy meeting will convene immuno-oncology researchers, cancer immunotherapy developers, and technology providers to discuss current challenges and opportunities - from discovery immuno-oncology to clinical studies; share latest technologies and development approaches; discuss advances in adoptive T-cell therapies and combinations, as well as to provide updates on clinical findings.

Who should attend: Directors, Managers, Researchers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as oncology, immunology, and cancer immunotherapy.

Topics will include, but are not limited to: 

Immuno-Oncology 

  • Biology of tumor micro-environments and immune checkpoint pathways
  • Novel and emerging tumor antigens for targeting
  • Mechanisms underlying success or failure of treatment

Cancer Immunotherapy Strategies 

  • Monoclonal antibodies
  • Checkpoint inhibitors
  • T-Cell directed therapies
    • CAR-T
    • TCR
    • TIL
  • Non-T-Cell directed approaches
    • T-regulatory cells, antigen-presenting cells, myeloid suppressor cells
  • Combination therapies
  • Updates on clinical studies

Technological Innovations 

  • Predictive preclinical models
  • T-cell engineering, gene therapy and gene editing
  • Biomarker development

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is August 7, 2015. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Kip Harry
Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z)
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 

Premier Sponsors:  

Elsevier   

Jackson Laboratory - small logo 

 NanoString2   

 Precision for Medicine 

SeraCare(2)

Silicon Biosystems

Thomson Reuters-Large